Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

Journal of Bone and Mineral Research

Volumn 26, Issue 2, 2011, Pages 397-404

  Cummings, Steven R ^a   McClung, Michael ^b   Reginster, Jean Yves ^c   Cox, David ^d   Mitlak, Bruce ^d   Stock, John ^d   Amewou Atisso, Messan ^d   Powles, Trevor ^e   Miller, Paul ^f   Zanchetta, José ^g   Christiansen, Claus ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON OSTEOPOROSIS CENTER   (United States)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d ELI LILLY AND COMPANY   (United States)

^e Parkside Oncology Clinic   (United Kingdom)

^f University of Colorado Health Sciences Center   (United States)

^g Instituto de Investigaciones Metabolicas   (Argentina)

^h NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

ARZOXIFENE; BREAST CANCER; CONTROLLED TRIAL; FRACTURE; OSTEOPOROSIS; RANDOMIZED; SERMS; VERTEBRAL FRACTURE

Indexed keywords

ARZOXIFENE; CALCIUM; PLACEBO; VITAMIN D;

ACUTE CHOLECYSTITIS; ADENOCARCINOMA; ADULT; AGED; ARTICLE; ASTHMA; BONE DENSITY; BONE NECROSIS; BONE TURNOVER; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONSTIPATION; COUGHING; DEEP VEIN THROMBOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; LUNG EMBOLISM; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE CRAMP; MUSCLE SPASM; NEOPLASM; OSTEOPOROSIS; PNEUMONIA; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; UPPER RESPIRATORY TRACT INFECTION; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VULVOVAGINITIS;

EID: 79251498941     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.191     Document Type: Article

References (21)

1. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-1388.
2. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282: 637-645.
3. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-137.
4. Palkowitz AD, Glasebrook AL, Thrasher KJ, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)] benzothiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem. 1997; 40: 1407-1416.
5. Zanchetta J, Palacios S, Cox D, Stock J, Dowsett S, Kendler D., Arzoxifene versus raloxifene: 12-month effects on bone mineral density, bone turnover markers, and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20 (Suppl 1): S14.
6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Womens Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
7. Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R., Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007; 24: 361-379.
8. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359: 697-708.
9. Genant HK, Wu CY, van KC, Nevitt MC., Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-1148.
10. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18: 1947-1954.
11. Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007; 298: 2381-2388.
12. Kurman RJ, Norris HJ., Endometrial hyperplasia and related cellular changes. In:, Kurman RJ, ed. Blausteins Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag; 1994: 411-427.
13. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189-2197. Erratum in JAMA 1999;282:2124.
14. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23: 1923-1934.
15. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362: 686-696.
16. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Womens Health Initiative randomized trial. JAMA. 2003; 290: 1729-1738.
17. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009; 16: 1109-1115.
18. Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002; 287: 847-857.
19. Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM., Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol. 2009; 305: 12-21.
20. Vegeto E, Cuzzocrea S, Crisafulli C, et al. Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation. Endocrinology. 2010; 151: 174-184.
21. Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330-339.